This slide was created under the auspices of Professional Postgraduate Services® through an unrestricted educational grant.
- As was the case for the primary end point, results for stroke in ALLHAT were consistent across the predefined subgroups (shown in the slide), as well as for participants with and without CHD at baseline.
- No difference emerged between amlodipine besylate and chorthalidone with respect to the secondary outcome of stroke.
- Blacks treated with lisinopril demonstrated a significantly greater risk of stroke compared with those treated with chlorthalidone (P<0.001). This effect was not observed in whites (P=0.96).